For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
12
references
 Top references
cited by
35
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      713
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Age as an independent prognostic factor for survival of localised synovial sarcoma patients

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          We performed a retrospective nationwide study to explore age as a prognostic factor in synovial sarcoma patients.

          Methods:

          Data on 613 synovial sarcoma patients were obtained from the Netherlands Cancer Registry. The prognostic relevance of age groups (children, adolescent and young adults (AYAs), adults, and elderly) was estimated by Kaplan–Meier survival curves and multivariable Cox-proportional hazards modelling.

          Results:

          A total of 461 patients had localised disease at diagnosis. The 5-year overall survival (OS) was 89.3±4.6%, 73.0±3.8%, 54.7±3.6%, and 43.0±7.0% in children ( n=54), AYAs ( n=148), adults ( n=204), and elderly ( n=55), respectively. Treatment modalities had no significant effect on survival in the univariable analysis. Multivariable analysis identified age at diagnosis, tumour localisation, and tumour size as significant factors affecting OS. Both tumour localisation and size were equally distributed over the age groups.

          Conclusions:

          We show that outcome of synovial sarcoma patients significantly decreases with age regardless of primary tumour site, size, and treatment.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database.

          Andrea Ferrari, Iyad Sultan, Tseng Huang … (2011)
          Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan. The impact of age on disease features and outcome is unclear. We analyzed the clinical features and outcome of all STS cases registered between 1973 and 2006 in the SEER database. There were 48,012 cases that met the selection criteria. Individuals less than 20 years of age represented 5.6%, with rhabdomyosarcoma being the most common subtype. In adults, the most common types were Kaposi sarcoma, fibrohistiocytic tumors, and leiomyosarcoma. Rhabdomyosarcoma was the only entity with a median age <20 years. Male predominance (male/female of 1.5:1) was noticed for almost all types of STS, except for alveolar soft part sarcoma and leiomyosarcoma. Tumor stage was similar across different age groups. Younger patients (<50 years) had significantly better survival than older patients (88.8 ± 0.2% vs. 40 ± 0.3%, P < 0.001), but for most histologies the survival decline with advancing age was gradual and did not occur abruptly at the onset of adulthood. The decline in survival with advancing age was particularly significant for rhabdomyosarcoma. With few exceptions, the clinical features of STS are similar in children and adults. However, individuals over 50 years of age have an inferior survival. Copyright © 2011 Wiley-Liss, Inc.
          Article 0 comments Cited 96 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients.

            Ruth Galindo, Michela Casanova, Sameer Yasir … (2009)
            Synovial sarcoma (SS) is a typical soft tissue sarcoma subtype crosswise between the pediatric and the adult age groups. Less satisfactory overall outcome has been recorded in adult series. This study compares clinical features and outcomes of SS across the different age groups, by analyzing 1268 cases, 213 children/adolescents (
            Article 0 comments Cited 89 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.

              Andrea Ferrari, Alessandro Gronchi, Michela Casanova … (2004)
              The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used for pediatric and adult patients. The current retrospective analysis examined a large group of patients of all ages who were treated at a single institution over a 30-year period. The study included 271 patients who ranged in age from 5 years to 87 years; 255 had localized disease, which was macroscopically resected in 215 cases and deemed unresectable at diagnosis in 40 cases. Chemotherapy was administered to 41% of patients, corresponding to 76% of patients age or 16 years and 30 years, respectively). Chemotherapy was used more commonly for children than for adults. Among patients with surgically resected disease, the 5-year metastasis-free survival (MFS) rate was 60% for those who were treated with chemotherapy and 48% for those who were not; the benefit associated with chemotherapy use appeared to be greatest for patients age > or = 17 years who had tumors measuring > 5 cm (MFS, 47% [chemotherapy] vs. 27% [no chemotherapy]). In the subgroup of patients with measurable disease, the rate of tumor response to chemotherapy was approximately 48%. Although the authors await more convincing proof of the efficacy of adjuvant chemotherapy in the treatment of adult soft tissue sarcoma, they recommend that patients with high-risk SS (tumor size > 5 cm) be the first to be considered for this type of treatment.
              Article 0 comments Cited 84 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Br J Cancer
                Journal ID (iso-abbrev): Br. J. Cancer
                Title: British Journal of Cancer
                Publisher: Nature Publishing Group
                ISSN (Print): 0007-0920
                ISSN (Electronic): 1532-1827
                Publication date (Print): 01 December 2015
                Publication date (Electronic): 10 November 2015
                Volume: 113
                Issue: 11
                Pages: 1602-1606
                Affiliations
                [1 ]Department of Medical Oncology, Radboud University Medical Center , PO Box 9101, 6500 HB Nijmegen, The Netherlands
                [2 ]Netherlands Comprehensive Cancer Organisation (IKNL) , PO Box 19079, 3501 DB Utrecht, The Netherlands
                [3 ]Health Evidence, Radboudumc , PO Box 9101, 6500 HB Nijmegen, The Netherlands
                [4 ]Radiotherapy, Antoni van Leeuwenhoek hospital – the Netherlands Cancer Institute , PO Box 90203, 1006 BE Amsterdam, The Netherlands
                [5 ]The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust , London, UK
                Author notes
                Article
                Publisher Item ID: bjc2015375
                DOI: 10.1038/bjc.2015.375
                PMC ID: 4705887
                PubMed ID: 26554650
                SO-VID: 919b6110-5851-4ba6-9d61-bf652cd431bc
                Copyright © Copyright © 2015 Cancer Research UK
                License:

                From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

                History
                Date received : 07 May 2015
                Date revision received : 01 October 2015
                Date accepted : 08 October 2015
                Categories
                Subject: Short Communication

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: synovial sarcoma,age,child,adolescents,elderly,therapy,prognosis,survival
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: synovial sarcoma, age, child, adolescents, elderly, therapy, prognosis, survival

                Comments

                Comment on this article

                scite_

                Similar content713

                See all similar

                Cited by34

                See all cited by

                Most referenced authors212

                See all reference authors